Tivantinib in combination with TKI inhibitors may provide a new strategy for the treatment of EGFR-mutated NSCLC and to some extent, may overcome NSCLC resistance to TKI inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.